COX-2 MEDIATES PRO-TUMORIGENIC EFFECTS OF PKCε IN PROSTATE CANCER

[1]  Yanlong Yang,et al.  The prognostic value of cyclooxygenase-2 expression in patients with esophageal cancer: evidence from a meta-analysis , 2017, OncoTargets and therapy.

[2]  J. Blando,et al.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway. , 2017, Cell reports.

[3]  Andrew H. Beck,et al.  Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. , 2017, Cancer research.

[4]  E. Dirican.  Mutations in PIK3CA Sensitize Breast Cancer Cells to Physiologic Levels of Aspirin. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[5]  A. Houston,et al.  Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? , 2015, British journal of pharmacology.

[6]  R. Santi,et al.  mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity , 2015, Endocrine-related cancer.

[7]  M. Kazanietz,et al.  PKCϵ Is an Essential Mediator of Prostate Cancer Bone Metastasis , 2015, Molecular Cancer Research.

[8]  M. Kazanietz,et al.  Protein kinase C and cancer: what we know and what we do not , 2014, Oncogene.

[9]  M. Kazanietz,et al.  Transcriptional Regulation of Oncogenic Protein Kinase Cϵ (PKCϵ) by STAT1 and Sp1 Proteins* , 2014, The Journal of Biological Chemistry.

[10]  R. Gomis,et al.  Cyclooxygenase‐2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice , 2014, BJU international.

[11]  A. Basu,et al.  The Multifunctional Protein Kinase C-ε in Cancer Development and Progression , 2014, Cancers.

[12]  F. Sinicrope,et al.  Aspirin and Colorectal Cancer: Back to the Future , 2013, Clinical Cancer Research.

[13]  V. Budhram-Mahadeo,et al.  Protein Kinase Cε-Calcineurin Cosignaling Downstream of Toll-Like Receptor 4 Downregulates Fibrosis and Induces Wound Healing Gene Expression in Cardiac Myofibroblasts , 2013, Molecular and Cellular Biology.

[14]  T. Uchiumi,et al.  EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer , 2013, Prostate Cancer and Prostatic Disease.

[15]  R. Dingledine,et al.  Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. , 2013, Trends in pharmacological sciences.

[16]  M. Kazanietz,et al.  Regulation of Transcriptional Networks by PKC Isozymes: Identification of c-Rel as a Key Transcription Factor for PKC-Regulated Genes , 2013, PloS one.

[17]  T. Uchiumi,et al.  Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. , 2013, Endocrine-related cancer.

[18]  T. Tammela,et al.  Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. , 2013, European journal of cancer.

[19]  R. Dingledine,et al.  Role of Prostaglandin Receptor EP2 in the Regulations of Cancer Cell Proliferation, Invasion, and Inflammation , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[20]  A. Takaoka,et al.  [NF-kappaB signaling pathway and inflammation]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[21]  Reiko Nishihara,et al.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.

[22]  J. Blando,et al.  Activation of Nuclear Factor κB (NF-κB) in Prostate Cancer Is Mediated by Protein Kinase C ϵ (PKCϵ)* , 2012, The Journal of Biological Chemistry.

[23]  Randall Harris,et al.  Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors , 2012, Journal of experimental pharmacology.

[24]  G. Robertson,et al.  Selenium-containing histone deacetylase inhibitors for melanoma management , 2012, Cancer biology & therapy.

[25]  M. Kazanietz,et al.  Proteins kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes , 2012, Oncogene.

[26]  M. Parmar,et al.  Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial , 2012, The Lancet. Oncology.

[27]  A. Armstrong.  The STAMPEDE trial and celecoxib: how to adapt? , 2012, The Lancet. Oncology.

[28]  J. Moscat,et al.  The atypical PKCs in inflammation: NF‐κB and beyond , 2012, Immunological reviews.

[29]  J. Kissil,et al.  Non-Small Cell Lung Carcinoma Cell Motility, Rac Activation and Metastatic Dissemination Are Mediated by Protein Kinase C Epsilon , 2012, PloS one.

[30]  V. Baron,et al.  Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo , 2011, The Prostate.

[31]  M. Choe,et al.  Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? , 2011, Korean journal of urology.

[32]  W. Zhong,et al.  Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. , 2011, Cancer research.

[33]  J. Blando,et al.  Transgenic overexpression of PKCε in the mouse prostate induces preneoplastic lesions , 2011, Cell cycle.

[34]  C. Busch,et al.  COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. , 2010, Cancer epidemiology.

[35]  R. Andreesen,et al.  Modular therapy approach in metastatic castration-refractory prostate cancer , 2010, World Journal of Urology.

[36]  R. DuBois,et al.  The role of COX-2 in intestinal inflammation and colorectal cancer , 2010, Oncogene.

[37]  A. Conney,et al.  Atorvastatin and Celecoxib in Combination Inhibits the Progression of Androgen-Dependent LNCaP Xenograft Prostate Tumors to Androgen Independence , 2010, Cancer Prevention Research.

[38]  M. Hamberg,et al.  Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells , 2009, Proceedings of the National Academy of Sciences.

[39]  Xiaoren Zhang,et al.  NF-κB Signaling Pathway, Inflammation and Colorectal Cancer , 2009, Cellular and Molecular Immunology.

[40]  Y. Nagashima,et al.  aPKCλ/ι promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 , 2009, Proceedings of the National Academy of Sciences.

[41]  M. Serrano,et al.  Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-κB activation and invasive prostate carcinoma , 2009, Proceedings of the National Academy of Sciences.

[42]  Y. Miki,et al.  Protein kinase Cdelta activates RelA/p65 and nuclear factor-kappaB signaling in response to tumor necrosis factor-alpha. , 2009, Cancer research.

[43]  Randall Harris,et al.  Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung , 2009, Inflammopharmacology.

[44]  Michael A Gorin,et al.  Protein kinase Cε: an oncogene and emerging tumor biomarker , 2009, Molecular Cancer.

[45]  E. Giovannucci,et al.  Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer , 2008, Clinical Cancer Research.

[46]  Shalini Jain,et al.  Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. , 2008, Cancer research.

[47]  N. Holden,et al.  Phorbol ester-stimulated NF-kappaB-dependent transcription: roles for isoforms of novel protein kinase C. , 2008, Cellular signalling.

[48]  Jiaoti Huang,et al.  A new prostate cancer therapeutic approach: Combination of androgen ablation with COX‐2 inhibitor , 2008, International journal of cancer.

[49]  M. Bosland,et al.  Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis: In vivo Evidence , 2007, Clinical Cancer Research.

[50]  D. Grignon,et al.  COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. , 2007, The Lancet. Oncology.

[51]  G. Wilding,et al.  Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. , 2007, Cancer research.

[52]  Louise R Howe,et al.  Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer , 2007, Breast Cancer Research.

[53]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[54]  M. Kazanietz,et al.  Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.

[55]  V. Adhami,et al.  Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo , 2007, Clinical Cancer Research.

[56]  W. Weichert,et al.  Overexpression of cyclooxygenase‐2 in human prostate carcinoma and prostatic intraepithelial neoplasia‐association with increased expression of polo‐like kinase‐1 , 2007, The Prostate.

[57]  J. Calixto,et al.  Pharmacological and Molecular Characterization of the Mechanisms Involved in Prostaglandin E2-Induced Mouse Paw Edema , 2006, Journal of Pharmacology and Experimental Therapeutics.

[58]  N. Narayanan,et al.  Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX‐2 inhibition , 2006, The Prostate.

[59]  L. Lessard,et al.  Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study , 2005, British Journal of Cancer.

[60]  R. Bolli,et al.  Role of the Protein Kinase C-&egr;–Raf-1–MEK-1/2–p44/42 MAPK Signaling Cascade in the Activation of Signal Transducers and Activators of Transcription 1 and 3 and Induction of Cyclooxygenase-2 After Ischemic Preconditioning , 2005, Circulation.

[61]  S. Merajver,et al.  Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. , 2005, Cancer research.

[62]  R. I. Carey,et al.  Cyclooxygenase‐2 inhibitor celecoxib augments chemotherapeutic drug‐induced apoptosis by enhancing activation of caspase‐3 and ‐9 in prostate cancer cells , 2005, International journal of cancer.

[63]  Akihiko Satoh,et al.  PKC-δ and -ε regulate NF-κB activation induced by cholecystokinin and TNF-α in pancreatic acinar cells , 2004 .

[64]  A. Neugut,et al.  Rates of caesarean section and instrumental vaginal delivery in nulliparous women after low concentration epidural infusions or opioid analgesia: systematic review , 2004, British medical journal.

[65]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[66]  J. Morrow,et al.  The glyceryl ester of prostaglandin E2 mobilizes calcium and activates signal transduction in RAW264.7 cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[67]  D. Terrian,et al.  Protein Kinase Cε Has the Potential to Advance the Recurrence of Human Prostate Cancer , 2002 .

[68]  P. Unger,et al.  Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. , 2000, Urology.

[69]  T. Hla,et al.  Expression of cyclooxygenase‐2 in prostate carcinoma , 2000, Cancer.

[70]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[71]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[72]  J. Pablo,et al.  Par‐4とPTENのin vivoにおける同時不活性化は相乗的にNF‐κB活性化と侵襲性前立腺癌を誘導する , 2009 .

[73]  Gao Tian-we.  Overexpression of cyclooxygenase-2 in human malignant melanoma , 2007 .

[74]  Tom S. Price,et al.  Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. , 2006, Gastroenterology.

[75]  Akihiko Satoh,et al.  PKC-delta and -epsilon regulate NF-kappaB activation induced by cholecystokinin and TNF-alpha in pancreatic acinar cells. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[76]  A. Dannenberg,et al.  COX-2 Inhibitors for the Prevention of Breast Cancer , 2004, Journal of Mammary Gland Biology and Neoplasia.

[77]  D. Terrian,et al.  Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. , 2002, Cancer research.

[78]  D. Bostwick,et al.  Over‐expression of cyclooxygenase‐2 in human prostate adenocarcinoma , 2000, The Prostate.